Literature DB >> 28551774

Continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin: pros and cons.

Maria Ida Maiorino1, Michela Petrizzo2, Giuseppe Bellastella3, Katherine Esposito3,2.   

Abstract

Continuous glucose monitoring associated with intensive insulin regimens represents a useful tool to lower HbA1c in selected adults with type 1 diabetes. Recent randomized controlled trials demonstrated greater glycemic benefits in type 1 diabetic patients treated with multiple daily injections of insulin and continuous glucose monitoring over usual care. These positive outcomes, however, are counter-balanced by several limitations that restrict the use of continuous glucose monitoring in the real life, including the apparent lack of benefits in children and pregnant diabetic women, the high cost, the stringent patients' selection, and the presence of a multi-disciplinary team with specific expertise. Pros and Cons of using continuous glucose monitoring in type 1 diabetic patients with multiple daily injections of insulin are here discussed.

Entities:  

Keywords:  CGM; Continuous subcutaneous insulin infusion; Multiple daily injections; Type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28551774     DOI: 10.1007/s12020-017-1328-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  18 in total

Review 1.  6. Glycemic Targets.

Authors: 
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

2.  Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study.

Authors:  Maria Ida Maiorino; Ofelia Casciano; Elisabetta Della Volpe; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito
Journal:  Endocrine       Date:  2015-07-17       Impact factor: 3.633

3.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline.

Authors:  Anne L Peters; Andrew J Ahmann; Tadej Battelino; Alison Evert; Irl B Hirsch; M Hassan Murad; William E Winter; Howard Wolpert
Journal:  J Clin Endocrinol Metab       Date:  2016-09-02       Impact factor: 5.958

5.  Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.

Authors:  Cornelis A J van Beers; J Hans DeVries; Susanne J Kleijer; Mark M Smits; Petronella H Geelhoed-Duijvestijn; Mark H H Kramer; Michaela Diamant; Frank J Snoek; Erik H Serné
Journal:  Lancet Diabetes Endocrinol       Date:  2016-09-15       Impact factor: 32.069

6.  Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.

Authors:  Roy W Beck; Tonya Riddlesworth; Katrina Ruedy; Andrew Ahmann; Richard Bergenstal; Stacie Haller; Craig Kollman; Davida Kruger; Janet B McGill; William Polonsky; Elena Toschi; Howard Wolpert; David Price
Journal:  JAMA       Date:  2017-01-24       Impact factor: 56.272

7.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

8.  Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data.

Authors:  John C Pickup; Suzanne C Freeman; Alex J Sutton
Journal:  BMJ       Date:  2011-07-07

9.  A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years.

Authors:  Nelly Mauras; Roy Beck; Dongyuan Xing; Katrina Ruedy; Bruce Buckingham; Michael Tansey; Neil H White; Stuart A Weinzimer; William Tamborlane; Craig Kollman
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

10.  Extended 6-month follow-up of a randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years.

Authors:  Michael Tansey; Stuart Weinzimer; Roy Beck; Katrina Ruedy; Peiyao Cheng; William Tamborlane; Craig Kollman; Nelly Mauras; Larry Fox; Julie Coffey; Neil H White
Journal:  Diabetes Care       Date:  2013-05       Impact factor: 19.112

View more
  3 in total

1.  Comment on "The pros and cons of continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin."

Authors:  Frontino Giulio; Favalli Valeria; Bonura Clara
Journal:  Endocrine       Date:  2017-06-23       Impact factor: 3.633

2.  Comment on "The pros and cons of continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin". Authors' reply.

Authors:  Michela Petrizzo; Maria Ida Maiorino; Katherine Esposito
Journal:  Endocrine       Date:  2018-02-05       Impact factor: 3.633

3.  Continuous glucose monitoring reduces pubertal hyperglycemia of type 1 diabetes.

Authors:  Benjamin Udoka Nwosu; Shamima Yeasmin; Sanaa Ayyoub; Shwetha Rupendu; Tony R Villalobos-Ortiz; Gabrielle Jasmin; Sadichchha Parajuli; Bita Zahedi; Emily Zitek-Morrison; Laura C Alonso; Bruce A Barton
Journal:  J Pediatr Endocrinol Metab       Date:  2020-07-28       Impact factor: 1.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.